CERo Therapeutics Holdings, Inc. Common Stock (CERO)
CERo Therapeutics Holdings, Inc. is a biopharmaceutical company focused on developing innovative cell therapies for cancer treatment. The company aims to enhance the immune system's ability to target and eliminate tumor cells through its proprietary technologies and therapeutic platforms.
Company News
CERo Therapeutics Holdings, Inc. (CERO) has appointed Chris Ehrlich as its new CEO. The company is advancing the development of next-generation engineered T cell therapeutics for cancer treatment, with plans to initiate clinical trials for its lead product candidate CER-1236 in early 2025 for acute myeloid leukemia (AML).
Shares of Kodiak Sciences Inc. (NASDAQ: KOD) fell sharply during Thursday’s session after the company reported a wider-than-expected fourth-quarter loss. Kodiak Sciences posted a quarterly loss of $1.13 per share, compared to market expectations for a loss of 77 cents per share. Kodiak Sciences shares dipped 19.9% to $5.97 on Thursday. Here a...